Rapid and sensitive spectrofluorimetric determination of enrofloxacin, levofloxacin and ofloxacin with 2,3,5,6-tetrachloro-p-benzoquinone

Ulu, Sevgi Tatar

doi:10.1016/j.saa.2008.12.046

Cited by 46 publications

(14 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several analytical methods have been described for the estimation of ENRO or PIRO alone or combined with other drugs in pharmaceutical formulations. Studies have employed high-performance liquid chromatography (HPLC), thin-layer chromatography (TLC), UV spectrophotometry, spectrofluorimetry, infrared spectroscopy, potentiometry, voltammetry, phosphorimetry, or chemiluminescence (Batrawi, Wahdan, Al-Rimawi, 2017;Starek et al, 2009;Kormosh, Hunka, Bazel, 2011;Ulu, 2009;Golovnev, Vasiliev, Kiriki, 2012;Khaled et al, 2012;Ensaifi, Khayamian, Taei, 2009;Souza et al, 2013;Pulgarin, Molina, Munoz, 2011).…”

Section: Introductionmentioning

confidence: 99%

Stability-indicating HPLC-DAD method for the simultaneous determination of fluoroquinolone in combination with a non-steroidal anti-inflammatory drug in pharmaceutical formulation

Araujo

Rosa

Amaral

et al. 2020

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

We developed and validated a stability-indicating assay method for the simultaneous determination of enrofloxacin and piroxicam in combination and in the presence of degradation products. Reversephase high-performance liquid chromatography analyses were carried out on a Vertisep C18 column and acetonitrile-water (48:52 v/v, pH 3.0) mobile phase with a 1.00 mL min −1 flow rate. The efficient chromatographic separation of these drugs and their forced degradation products was achieved in less than 5 min with a peak purity match factor higher than 950. The method used showed linearity in the concentration ranges of 0.25 to 16.0 μg mL −1 for enrofloxacin (r = 0.9997) and 0.125 to 8.0 μg mL −1 for piroxicam (r = 0.9999) as well as precision (relative standard deviation lower than 2%), accuracy (mean recovery 100 ± 2%), and robustness, according to ICH (International Conference on Harmonization) and AOAC (Association of Official Analytical Chemists) guidelines. This method can simultaneously determine the combination of these drugs in a veterinary formulation and separate the drug peaks from their forced degradation products. Additionally, its optimized chromatographic conditions can contribute to the quality control of this formulation in pharmaceutical manufacturing plants and minimize waste from the organic solvent.

show abstract

Section: Introductionmentioning

confidence: 99%

Stability-indicating HPLC-DAD method for the simultaneous determination of fluoroquinolone in combination with a non-steroidal anti-inflammatory drug in pharmaceutical formulation

Araujo

Rosa

Amaral

et al. 2020

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

show abstract

“…No official (pharmacopoeia) method has been found for the assay of GMF and MOX in their pharmaceutical formulations. Several methods have been reported on the determination of fluoroquinolones either in pure forms, in dosage forms, or in biological fluids like chromatography [3][4][5][6], capillary zone electrophoresis [7,8], electrochemistry [9][10][11], atomic absorption spectrometry [12,13], spectrofluorimetry [14][15][16], and spectrophotometric methods for GMF [17][18][19][20][21][22][23][24][25][26][27][28] or MOX [12,[29][30][31][32][33][34][35][36] (Tables 1 and 2). These methods were associated with some major drawbacks such as decreased Scheme 1: The chemical structure of the studied drugs.…”

Section: Introductionmentioning

confidence: 99%

Kinetic Spectrophotometric Determination of Gemifloxacin Mesylate and Moxifloxacin Hydrochloride in Pharmaceutical Preparations Using 4-Chloro-7-nitrobenzo-2-oxa-1,3-diazole

Wahed

Sheikh

Gouda

et al. 2014

Journal of Spectroscopy

View full text Add to dashboard Cite

Simple, sensitive, and accurate kinetic spectrophotometric method was proposed for the determination of gemifloxacin mesylate (GMF) and moxifloxacin hydrochloride (MOX) in pure forms and pharmaceutical preparations (tablets). The method is based on coupling the studied drugs with 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole (NBD-Cl) in the presence of alkaline borate buffer. Spectrophotometric measurement was achieved by recording the absorbance at 466 and 464 nm for GMF and MOX, respectively, after a fixed time of 20 and 15 min on a water bath adjusted at 70 ± 5°C for both drugs. The different experimental parameters affecting the development and stability of the color were carefully studied and optimized. The absorbance-concentration plots were linear over the ranges 0.5–8.0 and 2.0–12 μg mL−1for GMF and MOX, respectively. The limit of detection of the kinetic method was about 0.12 (2.47 × 10−7 M) and 0.36 (8.22 × 10−7 M) μg mL−1for GMF and MOX, respectively. The proposed methods have been applied and validated successfully with percentage relative standard deviation (RSD% ≤ 0.52) as precision and percentage relative error (RE% ≤ 1.33) as accuracy. The robustness of the proposed method was examined with recovery values that were 97.5–100.5 ± 1.3–1.9%. Statistical comparison of the results with the reference spectrophotometric methods shows excellent agreement and indicates no significant difference in accuracy or precision.

show abstract

“…Several methods have been reported for the determination of fluoroquinolones either in pure forms, in dosage forms, or in biological fluids like chromatography [3][4][5][6][7][8][9], capillary zone electrophoresis [10,11], electrochemistry [12][13][14][15], atomic absorption spectrometry [16,17], spectrofluorimetry [18][19][20][21] and spectrophotometric methods for GMF [22][23][24][25][26][27][28], MOX [16,[29][30][31][32][33] and GTF [16,[34][35][36][37][38][39][40][41][42][43][44]. These methods are associated with some major drawbacks such as decreased selectivity due to measurement in ultraviolet region [22,23,29,30] and/or de...…”

Section: Introductionmentioning

confidence: 99%

Kinetic spectrophotometric determination of some fluoroquinolone antibiotics in bulk and pharmaceutical preparations

Wahed¹,

Sheikh²,

Gouda³

et al. 2013

Bull. Chem. Soc. Eth.

View full text Add to dashboard Cite

ABSTRACT. A simple and sensitive kinetic spectrophotometric method was developed for the determination of some fluoroquinolonea antibiotics; gemifloxacin mesylate, moxifloxacin hydrochloride and gatifloxacin in bulk and in pharmaceutical preparations. The method is based upon a kinetic investigation of the oxidation reaction of the drugs with alkaline potassium permanganate at room temperature for a fixed time of 20 min for gemifloxacin and 15 min for moxifloxacin or gatifloxacin. The absorbance of the coloured manganate ion was measured at 610 nm. The absorbance-concentration plots were rectilinear over the ranges of 2.0-20, 4.0-24 and 4.0-40 µg mL −1 for gemifloxacin, moxifloxacin and gatifloxacin, respectively. The concentrations of the studied drugs were calculated using the corresponding calibration equations for the fixed-time method. The determination of the studied drugs by the fixed concentration and rate constant methods was also feasible with the calibration equations obtained but the fixed time method has been found to be more applicable. The different experimental parameters affecting the development and stability of the colors were carefully studied and optimized. The proposed method was applied to the determination of the studied drugs in pharmaceutical formulations.

show abstract

Rapid and sensitive spectrofluorimetric determination of enrofloxacin, levofloxacin and ofloxacin with 2,3,5,6-tetrachloro-p-benzoquinone

Cited by 46 publications

References 31 publications

Stability-indicating HPLC-DAD method for the simultaneous determination of fluoroquinolone in combination with a non-steroidal anti-inflammatory drug in pharmaceutical formulation

Stability-indicating HPLC-DAD method for the simultaneous determination of fluoroquinolone in combination with a non-steroidal anti-inflammatory drug in pharmaceutical formulation

Kinetic Spectrophotometric Determination of Gemifloxacin Mesylate and Moxifloxacin Hydrochloride in Pharmaceutical Preparations Using 4-Chloro-7-nitrobenzo-2-oxa-1,3-diazole

Kinetic spectrophotometric determination of some fluoroquinolone antibiotics in bulk and pharmaceutical preparations

Contact Info

Product

Resources

About